BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 16443548)

  • 1. Immunotherapy targeting 4-1BB and its ligand.
    Vinay DS; Kwon BS
    Int J Hematol; 2006 Jan; 83(1):23-8. PubMed ID: 16443548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
    Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS
    Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients.
    Blazar BR; Kwon BS; Panoskaltsis-Mortari A; Kwak KB; Peschon JJ; Taylor PA
    J Immunol; 2001 Mar; 166(5):3174-83. PubMed ID: 11207270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of 4-1BB (CD137) in cancer.
    Nam KO; Kang WJ; Kwon BS; Kim SJ; Lee HW
    Curr Cancer Drug Targets; 2005 Aug; 5(5):357-63. PubMed ID: 16101383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of 4-1BB in immune responses.
    Vinay DS; Kwon BS
    Semin Immunol; 1998 Dec; 10(6):481-9. PubMed ID: 9826581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.
    Lee J; Lee EN; Kim EY; Lee HJ; Park HJ; Sun CL; Lee SK; Joh JW; Lee KW; Kwon GY; Kim SJ
    Transplant Proc; 2005; 37(1):123-5. PubMed ID: 15808569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.
    Shuford WW; Klussman K; Tritchler DD; Loo DT; Chalupny J; Siadak AW; Brown TJ; Emswiler J; Raecho H; Larsen CP; Pearson TC; Ledbetter JA; Aruffo A; Mittler RS
    J Exp Med; 1997 Jul; 186(1):47-55. PubMed ID: 9206996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis.
    Maerten P; Kwon BS; Shen C; De Hertogh G; Cadot P; Bullens DM; Overbergh L; Mathieu C; Van Assche G; Geboes K; Rutgeerts P; Ceuppens JL
    Clin Exp Immunol; 2006 Feb; 143(2):228-36. PubMed ID: 16412046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
    Wen T; Bukczynski J; Watts TH
    J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costimulation of CD28- T lymphocytes by 4-1BB ligand.
    DeBenedette MA; Shahinian A; Mak TW; Watts TH
    J Immunol; 1997 Jan; 158(2):551-9. PubMed ID: 8992967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-1BB-mediated immunotherapy of rheumatoid arthritis.
    Seo SK; Choi JH; Kim YH; Kang WJ; Park HY; Suh JH; Choi BK; Vinay DS; Kwon BS
    Nat Med; 2004 Oct; 10(10):1088-94. PubMed ID: 15448685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with agonistic anti-CD137: two sides of a coin.
    Sun Y; Chen JH; Fu Y
    Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death.
    Hurtado JC; Kim YJ; Kwon BS
    J Immunol; 1997 Mar; 158(6):2600-9. PubMed ID: 9058792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes.
    Nam KO; Kang H; Shin SM; Cho KH; Kwon B; Kwon BS; Kim SJ; Lee HW
    J Immunol; 2005 Feb; 174(4):1898-905. PubMed ID: 15699116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF; Chen L; Zheng P; Liu Y
    Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
    Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
    Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.
    Foell JL; Diez-Mendiondo BI; Diez OH; Holzer U; Ruck P; Bapat AS; Hoffmann MK; Mittler RS; Dannecker GE
    Immunology; 2004 Sep; 113(1):89-98. PubMed ID: 15312139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling.
    Sun Y; Blink SE; Chen JH; Fu YX
    J Immunol; 2005 Jul; 175(2):884-90. PubMed ID: 16002686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.